Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study

Study limitation reported by the research below: “Regression to the mean is a plausible contributor to observed efficacy gains, as all participants were enrolled during documented disease breakthrough.”